Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 1.00 |
| ▸ | ESR2 | Q92731 | 8/20 | 0.65 |
| ▸ | ESR1 | P03372 | 7/20 | 0.65 |
| ▸ | HSD17B1 | P14061 | 2/20 | 0.60 |
| ▸ | HSD17B2 | P37059 | 2/20 | 0.60 |
| ▸ | MEN1 | O00255 | 2/20 | 0.58 |
| ▸ | NPC1 | O15118 | 2/20 | 0.58 |
| ▸ | RAB9A | P51151 | 2/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.58 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.58 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.56 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.56 |
| ▸ | TSHR | P16473 | 1/20 | 0.56 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.56 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.56 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.56 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.56 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.56 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.56 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Betanaphthol SCHEMBL11594695 | 1.00 | CYP1A2 (1.00) | CYP1A2ESR2ESR1HSD17B1HSD17B2 | |
| Betanaphthol SCHEMBL28781 | 1.00 | CYP1A2 (1.00) | CYP1A2ESR2ESR1HSD17B1HSD17B2 | |
| Betanaphthol SCHEMBL239472 | 1.00 | CYP1A2 (1.00) | CYP1A2ESR2ESR1HSD17B1HSD17B2 | |
| Betanaphthol SCHEMBL11678336 | 0.97 | CYP1A2 (0.94) | CYP1A2ESR2ESR1HSD17B1HSD17B2 | |
| Betanaphthol SCHEMBL7614330 | 0.97 | CYP1A2 (0.94) | CYP1A2ESR2ESR1HSD17B1HSD17B2 | |
| Betanaphthol SCHEMBL4336826 | 0.97 | CYP1A2 (0.94) | CYP1A2ESR2ESR1HSD17B1HSD17B2 | |
| Betanaphthol SCHEMBL14973607 | 0.97 | CYP1A2 (0.94) | CYP1A2ESR2ESR1HSD17B1HSD17B2 | |
| Betanaphthol SCHEMBL3592033 | 0.97 | CYP1A2 (0.94) | CYP1A2ESR2ESR1HSD17B1HSD17B2 | |
| Betanaphthol SCHEMBL8651479 | 0.97 | CYP1A2 (0.94) | CYP1A2ESR2ESR1HSD17B1HSD17B2 | |
| Betanaphthol SCHEMBL9116084 | 0.97 | CYP1A2 (0.94) | CYP1A2ESR2ESR1HSD17B1HSD17B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3603634-B1 | PHARMACEUTICAL COMPOSITION CONTAINING GLYCOPYRROLATE AND A BETA2 ADRENOCEPTOR AGONIST | NOVARTIS AG (CH) | 2025-02-12 | — | — | EP | claimed |
| EP-4370515-A1 | TRICYCLIC COMPOUNDS AS INHIBITORS OF KRAS | Incyte Corporation (US) | 2024-05-22 | — | — | EP | claimed |
| WO-2023287896-A1 | TRICYCLIC COMPOUNDS AS INHIBITORS OF KRAS | INCYTE CORPORATION (US) | 2023-01-19 | — | — | WO | claimed |
| WO-2022204112-A1 | IMIDAZOLE AND TRIAZOLE KRAS INHIBITORS | INCYTE CORPORATION (US) | 2022-09-29 | — | — | WO | claimed |
| WO-2025133077-A1 | METHOD FOR REMOVING AROMATIC SULPHONIC ACIDS AND THEIR SALTS FROM AQUEOUS PHASES | SALTIGO GMBH (DE) | 2025-06-26 | — | — | WO | disclosed |
| EP-4574815-A1 | PROCESS FOR THE SEPARATION OF AROMATIC SULPHONIC ACIDS AND SALTS FROM AQUEOUS PHASES | Saltigo GmbH (DE) | 2025-06-25 | — | — | EP | disclosed |
| CN-119930596-A | Organic compound and organic light-emitting device comprising same | 乐金显示有限公司 | 2025-05-06 | — | — | CN | disclosed |
| CN-113490850-B | Diagnostic and therapeutic methods for treating breast cancer | 基因泰克公司 | 2024-12-06 | — | — | CN | disclosed |
| US-20240317721-A1 | PYRAZOLYL DERIVATIVES AS INHIBITORS OF THE KRAS MUTANT PROTEIN | NOVARTIS AG (CH) | 2024-09-26 | — | — | US | disclosed |
| CN-118406189-A | Series of naphthyl tetrafunctional photosensitive monomers, and preparation method and application thereof | 福州大学 | 2024-07-30 | — | — | CN | disclosed |
| EP-4370515-A1 | TRICYCLIC COMPOUNDS AS INHIBITORS OF KRAS | Incyte Corporation (US) | 2024-05-22 | — | — | EP | disclosed |
| CN-117683051-A | Tetraheterocyclic compound, preparation method thereof, intermediate thereof and application thereof | 上海艾力斯医药科技股份有限公司 | 2024-03-12 | — | — | CN | disclosed |
| CN-116135901-A | Epoxy resin | DIC株式会社 | 2023-05-19 | — | — | CN | disclosed |
| WO-2023287896-A1 | TRICYCLIC COMPOUNDS AS INHIBITORS OF KRAS | INCYTE CORPORATION (US) | 2023-01-19 | — | — | WO | disclosed |
| US-20220370416-A1 | COMPOUNDS AND METHODS FOR TARGETED DEGRADATION OF KRAS | YALE UNIVERSITY | 2022-11-24 | — | — | US | disclosed |
| WO-2022221739-A1 | SMALL MOLECULE INHIBITORS OF KRAS G12D MUTANT | MERCK SHARP & DOHME CORP. (US) | 2022-10-20 | — | — | WO | disclosed |
| WO-2022204112-A1 | IMIDAZOLE AND TRIAZOLE KRAS INHIBITORS | INCYTE CORPORATION (US) | 2022-09-29 | — | — | WO | disclosed |
| CN-114894917-A | Detection and fingerprint spectrum construction method for volatile components of nardostachys chinensis bunge | 山东步长制药股份有限公司 | 2022-08-12 | — | — | CN | disclosed |
| CN-216457128-U | A filter pressing device for producing 2-bromine-7-hydroxynaphthalene | 安庆博曼生物技术有限公司 | 2022-05-10 | — | — | CN | disclosed |
| CN-216457128-U | A filter pressing device for producing 2-bromine-7-hydroxynaphthalene | 安庆博曼生物技术有限公司 | 2022-05-10 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220370416-A1 | COMPOUNDS AND METHODS FOR TARGETED DEGRADATION OF KRAS | KRAS, MDM2, VHL | CYP1A2 4459/4885ESR2 2017/4885ESR1 2510/4885 |
| US-20240317721-A1 | PYRAZOLYL DERIVATIVES AS INHIBITORS OF THE KRAS MUTANT PROTEIN | KRAS, NRAS, APC | CYP1A2 3678/4885ESR2 4319/4885ESR1 3696/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.